194 related articles for article (PubMed ID: 27532651)
1. Efficacy of direct factor Xa inhibitors compared to warfarin in preventing stroke in adults with non-valvular atrial fibrillation: a systematic review protocol.
Rasmussen KL; Hampton MD
JBI Database System Rev Implement Rep; 2016 Jun; 14(6):69-77. PubMed ID: 27532651
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation.
Coleman CI; Weeda ER; Nguyen E; Bunz TJ; Sood NA
Eur Heart J Qual Care Clin Outcomes; 2018 Oct; 4(4):328-329. PubMed ID: 29121212
[No Abstract] [Full Text] [Related]
3. [Anticoagulation for patients with non-valvular atrial fibrillation].
Mizoguchi T; Yasaka M
Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?
Plitt A; Giugliano RP
Future Cardiol; 2014 Mar; 10(2):153-5. PubMed ID: 24762238
[No Abstract] [Full Text] [Related]
5. Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Duke Med Health News; 2014 Sep; 20(9):3. PubMed ID: 25358137
[No Abstract] [Full Text] [Related]
6. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Piccini JP; Lopes RD; Mahaffey KW
Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Bioprosthetic Valves.
Kheiri B; Przybylowicz R; Simpson TF; Alhamoud H; Osman M; Dalouk K; Nazer B; Henrikson CA; Stecker E
Am J Cardiol; 2021 Mar; 142():140-141. PubMed ID: 33285096
[No Abstract] [Full Text] [Related]
8. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
[TBL] [Abstract][Full Text] [Related]
9. Novel anticoagulants for stroke prevention in patients with atrial fibrillation.
Jalota A; Scarabelli TM; Saravolatz L; Bakhsh MU; Agrawal P; Jalota R; Chen-Scarabelli C; Fuster V; Halperin J
Cardiovasc Drugs Ther; 2014 Jun; 28(3):247-62. PubMed ID: 24842559
[TBL] [Abstract][Full Text] [Related]
10. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Link MS; Giugliano RP; Ruff CT; Scirica BM; Huikuri H; Oto A; Crompton AE; Murphy SA; Lanz H; Mercuri MF; Antman EM; Braunwald E;
Circ Arrhythm Electrophysiol; 2017 Jan; 10(1):. PubMed ID: 28077507
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
Seeger JD; Bykov K; Bartels DB; Huybrechts K; Zint K; Schneeweiss S
Thromb Haemost; 2015 Nov; 114(6):1277-89. PubMed ID: 26446507
[TBL] [Abstract][Full Text] [Related]
12. [Progress of anticoagulation therapy in atrial fibrillation].
Hernández Olmedo M; Suárez Fernández C
Med Clin (Barc); 2015 Aug; 145(3):124-30. PubMed ID: 25192579
[TBL] [Abstract][Full Text] [Related]
13. Should patients on vitamin K antagonists be treated differently?
Pokorney SD; Granger CB
Eur Heart J; 2015 Jun; 36(23):1431-3. PubMed ID: 25694462
[No Abstract] [Full Text] [Related]
14. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial.
Melloni C; Dunning A; Granger CB; Thomas L; Khouri MG; Garcia DA; Hylek EM; Hanna M; Wallentin L; Gersh BJ; Douglas PS; Alexander JH; Lopes RD
Am J Med; 2017 Dec; 130(12):1440-1448.e1. PubMed ID: 28739198
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
[TBL] [Abstract][Full Text] [Related]
16. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
Spencer RJ; Amerena JV
Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
[TBL] [Abstract][Full Text] [Related]
19. Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.
McCarty D; Robinson A
Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):37-49. PubMed ID: 26378211
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
Xiang CL; Gong YZ; Zeng LJ; Wang R; Kea S; Chaudhary N; Tu RH; He Y
Acta Cardiol; 2016 Jun; 71(3):349-57. PubMed ID: 27594130
[No Abstract] [Full Text] [Related]
[Next] [New Search]
